Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Scientists at the Garvan Institute have flipped 30 years of thinking about mevalonate kinase deficiency (MKD), a rare inflammatory disorder. The real culprit isn't macrophages — it's malfunctioning natural killer (NK) cells. Even better, an existing drug called baricitinib has already shown promising results in a severely affected infant.
For three decades, researchers believed macrophages were the primary driver of mevalonate kinase deficiency (MKD), a rare genetic disorder that causes life-threatening inflammatory episodes. A new study published in Immunity by the Garvan Institute of Medical Research turns that assumption on its head — the real problem lies with natural killer (NK) cells, which fail to mature properly and can't destroy infected cells as they should.
When NK cells can't do their job, they overcompensate by flooding the body with interferon gamma, a powerful inflammatory signal that triggers the dangerous fevers, rashes, and organ damage seen in MKD patients. This discovery helps explain why roughly half of patients don't respond to current treatments, which only target the macrophage pathway.
The findings have already guided a real-world treatment: baricitinib, a JAK inhibitor already approved for rheumatoid arthritis and eczema, was added to an infant's regimen at Melbourne's Royal Children's Hospital — resulting in fewer flare-ups and healing of severe gut inflammation.
Key Takeaways:
Why it matters: With ~50% of MKD patients unresponsive to current therapies, this discovery opens a new, targeted treatment avenue using already-approved medications — potentially ending years-long diagnostic odysseys for patients with MKD and related disorders.